BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25450670)

  • 1. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
    Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
    Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
    Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
    Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
    Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
    Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
    Sodani K; Tiwari AK; Singh S; Patel A; Xiao ZJ; Chen JJ; Sun YL; Talele TT; Chen ZS
    Biochem Pharmacol; 2012 Jun; 83(12):1613-22. PubMed ID: 22414725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
    Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
    Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.
    Wu CP; Hsieh YJ; Murakami M; Vahedi S; Hsiao SH; Yeh N; Chou AW; Li YQ; Wu YS; Yu JS; Ambudkar SV
    Biochem Pharmacol; 2018 Sep; 155():316-325. PubMed ID: 30028995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
    Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
    J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin.
    Dornetshuber R; Heffeter P; Sulyok M; Schumacher R; Chiba P; Kopp S; Koellensperger G; Micksche M; Lemmens-Gruber R; Berger W
    Mol Nutr Food Res; 2009 Jul; 53(7):904-20. PubMed ID: 19517454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
    Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu L
    Br J Pharmacol; 2015 Aug; 172(16):4089-106. PubMed ID: 25988710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
    Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
    Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.